A citation-based method for searching scientific literature

Ilana Cass, Rae Lynn Baldwin, Taz Varkey, Roxana Moslehi, Steven A Narod, Beth Y Karlan. Cancer 2003
Times Cited: 340



Kathryn Alsop, Sian Fereday, Cliff Meldrum, Anna deFazio, Catherine Emmanuel, Joshy George, Alexander Dobrovic, Michael J Birrer, Penelope M Webb, Colin Stewart, Michael Friedlander, Stephen Fox, David Bowtell, Gillian Mitchell. J Clin Oncol 2012
Times Cited: 680




List of shared articles



Times cited

Hereditary ovarian tumour syndromes: current update on genetics and imaging.
K P Shanbhogue, A S Prasad, F E Ucisik-Keser, V S Katabathina, A C Morani. Clin Radiol 2021
0

Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
Mary B Daly, Tuya Pal, Michael P Berry, Saundra S Buys, Patricia Dickson, Susan M Domchek, Ahmed Elkhanany, Susan Friedman, Michael Goggins, Mollie L Hutton,[...]. J Natl Compr Canc Netw 2021
34

The Prognostic and Predictive Role of Somatic BRCA Mutations in Ovarian Cancer: Results from a Multicenter Cohort Study.
Angela Toss, Claudia Piombino, Elena Tenedini, Alessandra Bologna, Elisa Gasparini, Vittoria Tarantino, Maria Elisabetta Filieri, Luca Cottafavi, Filippo Giovanardi, Stefano Madrigali,[...]. Diagnostics (Basel) 2021
0

The Potential Predictors in Chemotherapy Sensitivity.
Eun-Kyu Kim, Hee-Chul Shin. Adv Exp Med Biol 2021
0

Epithelial ovarian cancer risk: A review of the current genetic landscape.
Nicola Flaum, Emma J Crosbie, Richard J Edmondson, Miriam J Smith, Dafydd G Evans. Clin Genet 2020
9

Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials.
Fengping Shao, Jun Liu, Yaoyun Duan, Li Li, Liqun Liu, Cai Zhang, Shanyang He. Biosci Rep 2020
7

Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline Resectable Pancreatic Cancer.
Talia Golan, Alex Barenboim, Guy Lahat, Ido Nachmany, Yacov Goykhman, Einat Shacham-Shmueli, Naama Halpern, Eli Brazowski, Ravit Geva, Ido Wolf,[...]. Ann Surg Oncol 2020
18

Lessons learned from understanding chemotherapy resistance in epithelial tubo-ovarian carcinoma from BRCA1and BRCA2mutation carriers.
Cécile Le Page, Setor Amuzu, Kurosh Rahimi, Walter Gotlieb, Jiannis Ragoussis, Patricia N Tonin. Semin Cancer Biol 2020
7


Olaparib maintenance for first-line treatment of ovarian cancer: will SOLO1 reset the standard of care?
Rowan E Miller, Shanthini M Crusz, Jonathan A Ledermann. Future Oncol 2019
9

Germline and somatic mutations of multi-gene panel in Chinese patients with epithelial ovarian cancer: a prospective cohort study.
Wenhui Li, Di Shao, Lei Li, Ming Wu, Shuiqing Ma, Xianjie Tan, Sen Zhong, Fengming Guo, Zhe Wang, Mingzhi Ye. J Ovarian Res 2019
9

Gynaecological neoplasms in common familial syndromes (Lynch and HBOC).
Carla Bartosch, Blaise Clarke, Tjalling Bosse. Pathology 2018
12



Prognosis of patients with BRCA1-associated ovarian carcinomas depends on TP53 accumulation status in tumor cells.
Iwona K Rzepecka, Lukasz M Szafron, Agnieszka Stys, Anna Felisiak-Golabek, Agnieszka Podgorska, Agnieszka Timorek, Piotr Sobiczewski, Barbara Pienkowska-Grela, Mona El-Bahrawy, Jolanta Kupryjanczyk. Gynecol Oncol 2017
5

Genomic insights in gynecologic cancer.
Erika Roddy, Jocelyn Chapman. Curr Probl Cancer 2017
5

Young Israeli women with epithelial ovarian cancer: prevalence of BRCA mutations and clinical correlates.
Limor Helpman, Omri Zidan, Eitan Friedman, Sarit Kalfon, Tamar Perri, Gilad Ben-Baruch, Jacob Korach. J Gynecol Oncol 2017
6

The First Nationwide Multicenter Prevalence Study of Germline BRCA1 and BRCA2 Mutations in Chinese Ovarian Cancer Patients.
Xiaohua Wu, Lingying Wu, Beihua Kong, Jihong Liu, Rutie Yin, Hao Wen, Ning Li, Hualei Bu, Yanling Feng, Qingli Li,[...]. Int J Gynecol Cancer 2017
30



Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients.
Ettore Capoluongo, Gillian Ellison, José Antonio López-Guerrero, Frederique Penault-Llorca, Marjolijn J L Ligtenberg, Susana Banerjee, Christian Singer, Eitan Friedman, Birgid Markiefka, Peter Schirmacher,[...]. Semin Oncol 2017
50

Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis.
Renaud Sabatier, Elise Lavit, Jessica Moretta, Eric Lambaudie, Tetsuro Noguchi, François Eisinger, Elisabeth Cherau, Magali Provansal, Doriane Livon, Laetitia Rabayrol,[...]. Fam Cancer 2016
4

Ovarian cancer: Status of homologous recombination pathway as a predictor of drug response.
Nicolas De Picciotto, Wulfran Cacheux, Arnaud Roth, Pierre O Chappuis, S Intidhar Labidi-Galy. Crit Rev Oncol Hematol 2016
32

Pharmacogenetic Predictors of Response.
Daniel L Hertz, James M Rae. Adv Exp Med Biol 2016
3

Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations.
Stephanie Jean, Jiaqi Li, Dionyssios Katsaros, Bradley Wubbenhorst, Kara N Maxwell, Lauren Fishbein, Michael W McLane, Chiara Benedetto, Emilie Marion Canuto, Nandita Mitra,[...]. Oncotarget 2016
3

Pharmacogenetics of cancer drugs.
Daniel L Hertz, James Rae. Annu Rev Med 2015
23

Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer.
Francisco J Candido-dos-Reis, Honglin Song, Ellen L Goode, Julie M Cunningham, Brooke L Fridley, Melissa C Larson, Kathryn Alsop, Ed Dicks, Patricia Harrington, Susan J Ramus,[...]. Clin Cancer Res 2015
93


The sooner the better: Genetic testing following ovarian cancer diagnosis.
E Fox, J McCuaig, R Demsky, C Shuman, D Chitayat, M Maganti, J Murphy, B Rosen, S Ferguson, S Randall Armel. Gynecol Oncol 2015
19


Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma.
David Fogelman, Elizabeth A Sugar, George Oliver, Neeraj Shah, Alison Klein, Christine Alewine, Huamin Wang, Milind Javle, Rachna Shroff, Robert A Wolff,[...]. Cancer Chemother Pharmacol 2015
36

High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation.
Tatiana V Gorodnova, Anna P Sokolenko, Alexandr O Ivantsov, Aglaya G Iyevleva, Evgeny N Suspitsin, Svetlana N Aleksakhina, Grigory A Yanus, Alexandr V Togo, Sergey Ya Maximov, Evgeny N Imyanitov. Cancer Lett 2015
54

[Hereditary ovarian carcinomas: clinico-biological features and treatment].
Anne Floquet, Eberhard Stoeckle, Sabrina Croce, Michel Longy, Gaétan Mc Grogan, Emmanuelle Barouk, Virginie Bubien, Delphine Garbay, Eglantine Joly, Frédéric Guyon. Bull Cancer 2014
3


"Platinum resistant" ovarian cancer: what is it, who to treat and how to measure benefit?
Alison Davis, Anna V Tinker, Michael Friedlander. Gynecol Oncol 2014
169